Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Green Tea Compounds Reduced Prostate Cancer Markers, Study
US researchers found that men with prostate cancer who consumed a mix of polyphenols found in green tea experienced a significant reduction in
generic viagra online
Better Access To Info And Dialogue With HCPs On Sexual Issues For Rheumatology Patients
Patients with rheumatic diseases want more information and better communication with healthcare professionals on the sexual issues related to their conditions, according to the results of a new study presented recently at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark.
News of the day
Calypso Medical Study Shows Potential For Improving Radiotherapy Treatment Accuracy Of Deadly Pancreatic Tumors
Calypso Medical Technologies, Inc., announced the publication of data from a clinician sponsored investigational study conducted at the University of Pennsylvania, demonstrating the utility of the Calypso® System in tracking tumor movement in the pancreas. The data will be presented at the 51st Annual Meeting of the American Association of Physicists in Medicine (AAPM), July 26-30, at the Anaheim Convention Center. "In areas of the body, such as the pancreas, that are susceptible to respiratory motion it can prove difficult to handle the spectrum of motion that can arise," said James Metz, M.D., Clinical Director, Department of Radiation Oncology, The University of Pennsylvania Health System.
Sexual Health

Cytokinetics To Present Phase IIa Clinical Trials Data On CK-1827452 At The 2009 Heart Failure Congress Of The European Society Of Cardiology

Cytokinetics, Incorporated (NASDAQ: CYTK) announced that data relating to two Phase IIa clinical trials evaluating CK-1827452, one in stable heart failure patients and one in patients with ischemic cardiomyopathy and angina, are scheduled to be presented in two poster presentations and in the late breaking trials session at the 2009 Heart Failure Congress of the European Society of Cardiology, to be held May 30-June 2, 2009, at the Nice Acropolis Palais des Congrç¨s et Expositions in Nice, France. Late Breaking Trials Session The late breaking presentation titled "The Selective Cardiac Myosin Activator, CK-1827452, Increases Systolic Function in Heart Failure" will be presented on Monday, June 1, 2009 from 11:00 AM - 12:30 PM Central European Time in the Apollon Auditorium by John Cleland, MD, FACC, FRCP, FESC, Professor of Cardiology, Castle Hill Hospital, University of Hull, United Kingdom. Poster Presentations Program #149: "Echocardiographic Detection of Increases in Ejection Fraction in Patients with Heart Failure Receiving the Selective Cardiac Myosin Activator, CK-1827452" is scheduled to be displayed in the session titled "Medical and Surgical Treatments Poster Session: Drug Therapy, Other" on Sunday, May 31, 2009 from 8:30 AM - 12:30 PM Central European Time in the Clinical Poster Zone. The poster will be moderated by Jonathan H. Goldman, MD, FACC, Chief Medical Officer, ICON Medical Imaging, Warrington, PA from 10:00 AM - 11:00 AM. Program #174: "Phase II Safety Study Evaluating the Novel Cardiac Myosin Activator, CK-1827452, in Patients with Ischemic Cardiomyopathy and Angina" is scheduled to be displayed in the session titled "Medical and Surgical Treatments Poster Session: Drug Therapy, Other" on Sunday, May 31, 2009 from 8:30 AM - 12:30 PM Central European Time in the Clinical Poster Zone. The poster will be moderated by Barry H. Greenberg, MD, Chair of the Safety Review Committee for this clinical trial and Director, Advanced Heart Failure Treatment Program, University of California, San Diego Medical Center from 10:00 AM - 11:00 AM. Cytokinetics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009